Rheumatic heart disease (RHD) is the chronic cardiac sequela of acute rheumatic fever (ARF), resulting from autoimmune inflammation triggered by untreated or inadequately treated group A Streptococcus (GAS) pharyngitis. RHD is characterized by permanent damage to the heart valves—most commonly the mitral valve—due to repeated or severe episodes of rheumatic carditis. The damage may lead to valvular stenosis or regurgitation, eventually progressing to heart failure, arrhythmias, or thromboembolic events.
II) Classification/Types
By Valve Involvement:
By Lesion Type:
By Chronicity:
RHD develops from persistent inflammation during episodes of acute rheumatic fever, where immune cross-reactivity between GAS M proteins and cardiac tissues leads to repeated injury. Inflammatory infiltration causes fibrinoid necrosis of valves, followed by fibrosis, commissural fusion, and calcification. Chronic valvular deformity leads to hemodynamic changes such as left atrial enlargement, pulmonary hypertension, and eventual ventricular dysfunction.
Etiology
II) Risk Factors
Drug Class | Example | Notes |
Antibiotics | Benzathine penicillin IM | Every 3–4 weeks for secondary prophylaxis |
Diuretics | Furosemide | For fluid overload/heart failure |
Beta-blockers | Metoprolol, Atenolol | Rate control in atrial fibrillation |
Anticoagulants | Warfarin | For AF with high thromboembolic risk or prior stroke |
Vasodilators | ACE inhibitors | Afterload reduction in regurgitant lesions |
Education
Screening
Vaccinations
Short-Term
Long-Term
Prognosis
HMD is a beacon of medical education, committed to forging a global network of physicians, medical students, and allied healthcare professionals.